EP MedSystems Adds Key Staff.

Health/Medical Writers

MT. ARLINGTON, N.J.--(BW HealthWire)--Jan. 7, 2002

EP MedSystems, Inc. (NASDAQ: EPMD) announced today the appointments of Dr. Praveen Dala-Krishna as Project Engineer and Kenneth Bagnell to Director of Operations.

Dr. Dala-Krishna joins EP MedSystems, Inc., bringing over 10-year's experience including significant accomplishments in biomedical engineering. Since 1998 Dala-Krishna has served as Sr. Consultant for Digitek Systems Corporation where his work in the areas of medical imaging equipment has contributed to product development at clients such as Medi-Max Technologies, Medi-Spares, Inc., Om Technologies, Acuson Corporation, and Biotechnologies, Inc. Dala-Krishna earned his Masters and PhD in BioEngineering from Drexel University and, as a research assistant at Drexel, he contributed to studies in the areas of sub-harmonic imaging and cardiovascular turbulence.

Kenneth Bagnell brings significant operations management experience to EP MedSystems, Inc. with particular expertise in manufacturing systems development and implementation. From 1998 until 2001 Bagnell served as Executive Vice President and General Manager for Cramer Company, a manufacturer of electro-mechanical devices for the process equipment industry. In the 1980's Bagnell was VP of Manufacturing for Garvey Corporation where he implemented a MAPICS ERP System including production control and cost system modules. As an independent consultant and as a consultant for SSA Mid-Atlantic, Bagnell has achieved significant operating successes for several corporations with major impacts on integrated manufacturing systems. Kenneth has a mechanical engineering background from Drexel University.

Reinhard Schmidt, EPMD's President and Chief Operating Officer, commented: "We are extremely pleased to bring the talent and expertise represented by Praveen Dala-Krishna and Ken Bagnell to EP MedSystems, Inc. These are important strategic additions to our management team and buttress our ability to drive product development and create the sophisticated and responsive manufacturing systems required by our market."

Mr. Schmidt stated further, "These staffings are in conjunction with operation changes that provide for separation of development activity from manufacturing operations. We expect this will help accelerate our time to market and insure we are prepared for the increased production requirements of our pending product approvals will require in the coming year."

EP MedSystems develops and markets cardiac electrophysiology ("EP") products used to diagnose and treat certain disorders of cardiac rhythm. The Company's EP product line includes the EP-WorkMate(R) Electrophysiology Workstation, the EP-3(TM) Stimulator, diagnostic electrophysiology catheters, internal cardioversion catheters and related disposable supplies. The Company is also involved in the development of an intracardiac ultrasound imaging system, expected to be on the market next year.

EPMD's ALERT(R) catheter is proprietary and used in tandem with the ALERT(R) Companion to deliver a bi-phasic low energy waveform used to convert atrial fibrillation to a normal (sinus) heart rhythm. The ALERT(R) System has been shown to use about 50 times less energy for cardioversion than the standard external "paddles". The Company has completed its clinical trials and is awaiting FDA approval for the ALERT(R) System. EPMD estimates that there are more than 5 million people worldwide with atrial fibrillation; a disease associated with reduced cardiac output, congestive heart failure, and stroke. For more information, visit our Website at www.epmedsystems.com.

This Release may contain certain statements of a forward-looking nature relating to future events or the future financial performance of the Company. Such forward-looking statements are only predictions and are subject to risks and uncertainties that could cause actual results or events to differ materially and adversely from the events discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's history of losses, uncertainty of future profitability and future liquidity needs; and risks regarding demand for new and existing products, including the ALERT(R) System and the ViewMate ultrasound system. The Company cautions investors and others to review the cautionary statements set forth in this Release and in the Company's reports filed with the Securities and Exchange Commission and cautions that other factors may prove to be important in affecting the Company's business and results of operations. Readers are cautioned not to place undue reliance on quotations, interviews, and other forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this report or to reflect the occurrence of anticipated events.